3 news items
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
RGNX
28 Mar 24
of our scientists and investigators, and further validates the clinically transformative nature of ABBV-RGX-314 as a potential one-time gene therapy
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
RGNX
5 Mar 24
of the AFFINITY DUCHENNE trial clinic assessments and home videos shared with trial investigators by caregivers illustrate that patients treated
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
RGNX
5 Mar 24
, with principal investigator
- Prev
- 1
- Next